IncellDx, BMS in Companion Diagnostic Deal
IncellDx Signs Agreement With Bristol-Myers Squibb Related to the Development of an Assay for a Companion Diagnostic Test
MENLO PARK, Calif., Oct. 29, 2013 (GLOBE NEWSWIRE) -- IncellDx, Inc. announced today that they have entered into an agreement with Bristol-Myers Squibb Company (NYSE:BMY) related to the development of an assay for potential application in a molecular companion diagnostic intended to identify patients likely to benefit from treatment with a Bristol-Myers Squibb drug that is currently under development.
The test will be based upon a modification of IncellDx's quantitative InCellCept assay, a cell-based instrument capable of quantifying molecular biomarkers inside intact cells. This allows protein and gene expression to be measured by distinct cell type, which aids both diagnosis and disease localization. If successful, the companies anticipate extending the relationship into development of a molecular companion diagnostic in which the assay would be used to determine phenotypic susceptibility of patients' disease prior to treatment.
This collaboration with Bristol-Myers Squibb highlights IncellDx's commitment to precision diagnostics and personalized medicine. "The agreement highlights the breadth of IncellDx's novel cellular multiplexing molecular technology," commented Bruce Patterson, MD, CEO of IncellDx.
Financial terms of the agreement were not disclosed.
About IncellDx Inc.
IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis, and organ transplant rejection. For more information, please visit www.incelldx.com.
CONTACT: Eric Hass
Posted: October 2013